JP6949206B2 - 抗体薬物複合体中間体の製造方法 - Google Patents
抗体薬物複合体中間体の製造方法 Download PDFInfo
- Publication number
- JP6949206B2 JP6949206B2 JP2020515844A JP2020515844A JP6949206B2 JP 6949206 B2 JP6949206 B2 JP 6949206B2 JP 2020515844 A JP2020515844 A JP 2020515844A JP 2020515844 A JP2020515844 A JP 2020515844A JP 6949206 B2 JP6949206 B2 JP 6949206B2
- Authority
- JP
- Japan
- Prior art keywords
- pab
- cit
- val
- reaction
- maa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 47
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims description 35
- 239000000611 antibody drug conjugate Substances 0.000 title claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 57
- 229940079593 drug Drugs 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 33
- 125000005647 linker group Chemical group 0.000 claims description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 22
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- 239000002254 cytotoxic agent Substances 0.000 claims description 17
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 150000007530 organic bases Chemical class 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 8
- 150000003852 triazoles Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- FPDWHGAQJGAILQ-UHFFFAOYSA-N C(O)(O)=O.[N+](=O)([O-])C1=CC=CC=C1.[N+](=O)([O-])C1=CC=CC=C1 Chemical compound C(O)(O)=O.[N+](=O)([O-])C1=CC=CC=C1.[N+](=O)([O-])C1=CC=CC=C1 FPDWHGAQJGAILQ-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229950010131 puromycin Drugs 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 108010044540 auristatin Proteins 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000012454 non-polar solvent Substances 0.000 claims description 4
- 239000010414 supernatant solution Substances 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 claims 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 claims 2
- WIQWGNXNIJSPQP-UHFFFAOYSA-N 1-hydroxytriazole-4-carboxylic acid Chemical compound OC(=O)C1=CN(O)N=N1 WIQWGNXNIJSPQP-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000010168 coupling process Methods 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000008878 coupling Effects 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 239000012043 crude product Substances 0.000 description 6
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- RHQGFVOXIOMBMC-UUMMFNFXSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC2c3ccccc3-c3ccccc23)C(C)C)cc1)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC2c3ccccc3-c3ccccc23)C(C)C)cc1)C(C)C RHQGFVOXIOMBMC-UUMMFNFXSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WZEAGSMYTVSXQA-XZZQEHRXSA-N [4-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methox Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](N)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 WZEAGSMYTVSXQA-XZZQEHRXSA-N 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- VEGGTWZUZGZKHY-GJZGRUSLSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)-n-[4-(hydroxymethyl)phenyl]pentanamide Chemical compound NC(=O)NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)NC1=CC=C(CO)C=C1 VEGGTWZUZGZKHY-GJZGRUSLSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940123752 RNA synthesis inhibitor Drugs 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- USMYACISHVPTHK-PXLJZGITSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound O=C([C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC(C=C1)=CC=C1COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 USMYACISHVPTHK-PXLJZGITSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- -1 barrubicin Chemical compound 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Description
反応A:Py−MAA−Val−Cit−PAB−OHを溶媒に溶解させ、ジ(p−ニトロベンゼン)カーボネートを加え、溶解するか、わずかに濁るまで撹拌した後、有機塩基を加え;
反応B:反応Aが終了した後に、トリアゾール類触媒、薬物部分D、有機塩基を加え、反応終了後、精製し、Py−MAA−Val−Cit−PAB−Dを得る方法であるのが好ましく、この際の精製は、pre−HPLCを使用して実施されることがより好ましい。
反応A:Py−MAA−Val−Cit−PABをDMFに溶解させ、ジ(p−ニトロベンゼン)カーボネートを加え、溶解するか、わずかに濁るまで撹拌した後、N,N−ジイソプロピルエチルアミンを滴下し、分離・精製してPy−MAA−Val−Cit−PAB−PNPを得;
反応B:Py−MAA−Val−Cit−PAB−PNPをDMFに溶解させ、1−ヒドロキシベンゾトリアゾール、MMAE、N,N−ジイソプロピルエチルアミン及びピリジンを加え、反応終了後、pre−HPLCによる精製を行い、構造式(1)で表される化合物Py−MAA−Val−Cit−PAB−MMAEを得る、ことを含む。
ここで、前記Py−MAA−Val−Cit−PAB−PNPの構造は、以下の通りである。
(1)反応Aの反応液を遠心し、上清液を取得し、
(2)上清液に溶媒1を加え、均一に撹拌し、
(3)0〜10℃の条件下で溶媒2を滴下し、均一に撹拌し、
(4)吸引ろ過し、ケーキを取得し、
(5)ケーキを溶媒3と溶媒4の混合溶液に再溶解させ、
(6)0〜10℃の条件下で溶媒5に滴下し、撹拌し、
(7)吸引ろ過して類白色粉末として精製後のPy−MAA−Val−Cit−PAB−PNPを得る。
ここで、溶媒1は、中極性溶媒であり、好ましくは、酢酸エチル、ジクロロメタン、メタノール、メチルtert−ブチルエーテルなどであり、最も好ましくは、酢酸エチルであり、
溶媒2は、低極性溶媒であり、好ましくは、石油エーテル、n−ヘキサン、n−ペンタン、シクロヘキサンなどであり、最も好ましくは、石油エーテルであり、
溶媒3及び4は、Py−MAA−Val−Cit−PAB−PNPが溶解しやすい溶媒であり、好ましくは、酢酸、トリフルオロ酢酸、ギ酸、メタノール、エタノールなどであり、最も好ましくは、酢酸及びメタノールであり、
溶媒5は、Py−MAA−Val−Cit−PAB−PNPが溶解しにくい溶媒であり、好ましくは、アセトニトリル、酢酸エチル、ジクロロメタン、水などであり、最も好ましくは、水である。
前記溶媒1と溶媒2と溶媒3と溶媒4とPy−MAA−Val−Cit−PABの体積重量比は、40〜100:80〜200:5〜15:1〜3:15〜30:1である。
(1)中間生成物Aを遠心し、上清液を取得し、
(2)上清液に酢酸エチルを加え、均一に撹拌し、
(3)0〜10℃の条件下で石油エーテルを滴下し、均一に撹拌し、
(4)吸引ろ過し、ケーキを取得し、
(5)ケーキを酢酸とメタノールの混合溶液に再溶解させ、
(6)0〜10℃の条件下で精製水を滴下し、撹拌し、
(7)吸引ろ過して類白色粉末として精製後のPy−MAA−Val−Cit−PAB−PNPを得る。
他に特に定義されない限り、本明細書で使用される全ての技術用語及び科学用語は、当業者によって理解されるものと同じ意味を有する。
Claims (15)
- 反応A:Py−MAA−Val−Cit−PAB−OHを溶媒に溶解させ、ジ(p−ニトロベンゼン)カーボネートを加え、溶解するかわずかに濁るまで撹拌した後、有機塩基を加え、
反応B:反応A終了後、トリアゾール類触媒、薬物部分D、有機塩基を加え、反応終了後、精製し、Py−MAA−Val−Cit−PAB−Dを得る、ことを特徴とする請求項1に記載の製造方法。 - 前記薬物部分Dは、アウリスタチン(auristatin)類細胞毒性剤、アントラマイシン(Anthramycin)類細胞毒性剤、アントラサイクリン(anthracycline)類細胞毒性剤又はピューロマイシン(puromycin)細胞毒性剤であることを特徴とする請求項1又は2に記載の製造方法。
- 前記アウリスタチン(auristatin)類細胞毒性剤は、MMAE、MMAF又はMMADであり、前記アントラマイシン(Anthramycin)類細胞毒性剤は、アントラマイシンであり、前記アントラサイクリン(anthracycline)類細胞毒性剤は、ダウノルビシン、ドキソルビシン、エピルビシン、イダルビシン、バルルビシン又はミトキサントロンであり、前記ピューロマイシン(puromycin)細胞毒性剤は、ピューロマイシンであることを特徴とする請求項3に記載の製造方法。
- 前記溶媒は、極性溶媒及び/又は非極性溶媒であり、前記極性溶媒はDMF、DMA、NMPの1種又は複数種であり、前記非極性溶媒はジクロロメタン、四塩化炭素の1種又は複数種である、ことを特徴とする請求項2〜5のいずれか1項に記載の製造方法。
- 前記有機塩基はN,N−ジイソプロピルエチルアミン、トリエチルアミン、ピリジンの1種又は複数種である、ことを特徴とする請求項2〜6のいずれか1項に記載の製造方法。
- 前記トリアゾール類触媒は1−ヒドロキシベンゾトリアゾール、1−ヒドロキシ−7−アザベンゾトリアゾール、1−ヒドロキシ−1H−1,2,3−トリアゾール−4−カルボン酸エチルの1種又は複数種である、ことを特徴とする請求項2〜7のいずれか1項に記載の製造方法。
- 前記反応Aにおいて、ジ(p−ニトロベンゼン)カーボネートの添加前、反応系の温度を5〜15℃に制御する、ことを特徴とする請求項2〜8のいずれか1項に記載の製造方法。
- 前記反応Bにおいて、トリアゾール類触媒の添加前、反応系の温度を5〜15℃に制御する、ことを特徴とする請求項2〜9のいずれか1項に記載の製造方法。
- 前記反応Aにおいて、Py−MAA−Val−Cit−PAB−OHとジ(p−ニトロベンゼン)カーボネートと有機塩基とのモル比が1:1〜5:1〜3である、ことを特徴とする請求項2〜10のいずれか1項に記載の製造方法。
- 前記反応Bにおいて、トリアゾール類触媒とMMAEと有機塩基とPy−MAA−Val−Cit−PAB−OHとのモル比が1〜3:1〜3:1.5〜30:1である、ことを特徴とする請求項2〜11のいずれか1項に記載の製造方法。
- 前記反応B終了後、pre−HPLCにより精製し、Py−MAA−Val−Cit−PAB−Dを得る、ことを特徴とする請求項2〜12のいずれか1項に記載の製造方法。
- 反応Aは、以下の方法により精製してPy−MAA−Val−Cit−PAB−PNPを得ることを特徴とする請求項2〜13のいずれか1項に記載の製造方法。
(1)反応Aの反応液を遠心し、上清液を得、
(2)上清液に溶媒1を加え、均一に撹拌し、
(3)0〜10℃条件下で溶媒2滴下し、均一に撹拌し、
(4)吸引ろ過し、ケーキを得、
(5)ケーキを溶媒3と溶媒4の混合溶液に再溶解させ、
(6)0〜10℃条件下で溶媒5に滴下し、撹拌し、
(7)吸引ろ過して類白色粉末として精製後のPy−MAA−Val−Cit−PAB−PNPを得る(ここで、溶媒1は、中極性溶媒であり、溶媒2は、低極性溶媒であり、溶媒3及び4は、Py−MAA−Val−Cit−PAB−PNPが溶解しやすい溶媒であり、溶媒5はアセトニトリル、酢酸エチル、ジクロロメタン又は水である)。 - 前記反応A及びBはいずれも窒素ガス保護下で行われる、ことを特徴とする請求項2〜14のいずれか1項に記載の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810487856.4 | 2018-05-21 | ||
CN201810487856.4A CN110507824A (zh) | 2018-05-21 | 2018-05-21 | 一种抗间皮素抗体及其抗体药物缀合物 |
PCT/CN2019/087641 WO2019223653A1 (zh) | 2018-05-21 | 2019-05-20 | 一种抗体药物偶联物中间体的制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020533398A JP2020533398A (ja) | 2020-11-19 |
JP6949206B2 true JP6949206B2 (ja) | 2021-10-13 |
Family
ID=68616215
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020535025A Pending JP2021523874A (ja) | 2018-05-21 | 2019-05-15 | 抗メソセリン抗体およびその抗体薬物コンジュゲート |
JP2020515844A Active JP6949206B2 (ja) | 2018-05-21 | 2019-05-20 | 抗体薬物複合体中間体の製造方法 |
JP2023100937A Pending JP2023134472A (ja) | 2018-05-21 | 2023-06-20 | 抗メソセリン抗体およびその抗体薬物コンジュゲート |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020535025A Pending JP2021523874A (ja) | 2018-05-21 | 2019-05-15 | 抗メソセリン抗体およびその抗体薬物コンジュゲート |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023100937A Pending JP2023134472A (ja) | 2018-05-21 | 2023-06-20 | 抗メソセリン抗体およびその抗体薬物コンジュゲート |
Country Status (12)
Country | Link |
---|---|
US (2) | US20220056147A1 (ja) |
EP (2) | EP3695852A4 (ja) |
JP (3) | JP2021523874A (ja) |
KR (3) | KR20200120728A (ja) |
CN (3) | CN110507824A (ja) |
AU (2) | AU2019272250B2 (ja) |
BR (2) | BR112020014380A2 (ja) |
CA (2) | CA3082160C (ja) |
RU (2) | RU2747995C1 (ja) |
SG (2) | SG11202011159QA (ja) |
TW (1) | TWI714092B (ja) |
WO (2) | WO2019223579A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11717575B2 (en) | 2019-05-20 | 2023-08-08 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
CN111560072B (zh) * | 2020-07-16 | 2020-12-11 | 上海恒润达生生物科技有限公司 | 抗人msln抗体以及靶向msln的免疫效应细胞 |
EP4129335A4 (en) | 2020-09-01 | 2024-04-24 | Remegen Co Ltd | ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS |
JP2023169444A (ja) * | 2020-10-01 | 2023-11-30 | 株式会社Epsilon Molecular Engineering | 標的タンパク質と結合し得る架橋ペプチド、当該架橋ペプチドの作製方法、及び当該架橋ペプチドを有効成分とする医薬組成物 |
KR20230165255A (ko) * | 2021-03-31 | 2023-12-05 | 레메젠 코, 리미티드 | 항체 약물 접합체 중간체의 제조 및 정제 방법 |
WO2022237666A1 (zh) | 2021-05-08 | 2022-11-17 | 荣昌生物制药(烟台)股份有限公司 | 一种抗Claudin18.2抗体及其抗体药物偶联物 |
WO2022262859A1 (zh) * | 2021-06-18 | 2022-12-22 | 江苏先声药业有限公司 | 抗人msln人源化抗体及其应用 |
CN116410332A (zh) * | 2021-12-29 | 2023-07-11 | 上海细胞治疗集团有限公司 | 抗间皮素纳米抗体嵌合抗原受体及其应用 |
WO2023157989A1 (ko) * | 2022-02-17 | 2023-08-24 | 주식회사 노벨티노빌리티 | 항체-약물 접합체 |
CN117843793A (zh) * | 2024-03-07 | 2024-04-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1507556T1 (sl) * | 2002-05-02 | 2016-10-28 | Wyeth Holdings Llc | Konjugati kaliheamicinski derivat-nosilec |
SG195524A1 (en) * | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
RS54163B1 (en) * | 2006-05-30 | 2015-12-31 | Genentech Inc. | ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE |
UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
BR112013014527A2 (pt) * | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
AU2012235817B2 (en) * | 2011-04-01 | 2016-03-10 | Wyeth Llc | Antibody-drug conjugates |
AR090903A1 (es) * | 2012-05-01 | 2014-12-17 | Genentech Inc | Anticuerpos e inmunoconjugados anti-pmel17 |
CN106279352B (zh) * | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
AU2016308539B2 (en) * | 2015-08-14 | 2019-01-24 | Remegen Co., Ltd. | Covalent linkers in antibody-drug conjugates and methods of making and using the same |
WO2017172907A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
WO2017177337A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
JP6727052B2 (ja) * | 2016-07-19 | 2020-07-22 | 株式会社日立製作所 | 生体分子分析用デバイス及び生体分子分析装置 |
CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
CA3078676A1 (en) * | 2017-10-30 | 2019-05-09 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
-
2018
- 2018-05-21 CN CN201810487856.4A patent/CN110507824A/zh not_active Withdrawn
-
2019
- 2019-05-15 EP EP19808424.6A patent/EP3695852A4/en active Pending
- 2019-05-15 BR BR112020014380-4A patent/BR112020014380A2/pt unknown
- 2019-05-15 KR KR1020207026535A patent/KR20200120728A/ko not_active IP Right Cessation
- 2019-05-15 CA CA3082160A patent/CA3082160C/en active Active
- 2019-05-15 WO PCT/CN2019/086977 patent/WO2019223579A1/zh unknown
- 2019-05-15 US US16/644,842 patent/US20220056147A1/en active Pending
- 2019-05-15 RU RU2020113275A patent/RU2747995C1/ru active
- 2019-05-15 SG SG11202011159QA patent/SG11202011159QA/en unknown
- 2019-05-15 AU AU2019272250A patent/AU2019272250B2/en active Active
- 2019-05-15 JP JP2020535025A patent/JP2021523874A/ja active Pending
- 2019-05-15 CN CN201980002416.8A patent/CN110740754B/zh active Active
- 2019-05-15 KR KR1020237030872A patent/KR20230135164A/ko not_active Application Discontinuation
- 2019-05-20 WO PCT/CN2019/087641 patent/WO2019223653A1/zh unknown
- 2019-05-20 US US16/618,110 patent/US20200138968A1/en active Pending
- 2019-05-20 SG SG11202006515VA patent/SG11202006515VA/en unknown
- 2019-05-20 KR KR1020207020184A patent/KR102454638B1/ko active IP Right Grant
- 2019-05-20 AU AU2019268215A patent/AU2019268215B2/en active Active
- 2019-05-20 BR BR112020005596-4A patent/BR112020005596A2/pt unknown
- 2019-05-20 RU RU2019142484A patent/RU2724436C1/ru active
- 2019-05-20 EP EP19807031.0A patent/EP3797795A4/en active Pending
- 2019-05-20 CN CN201980002405.XA patent/CN110740753A/zh active Pending
- 2019-05-20 JP JP2020515844A patent/JP6949206B2/ja active Active
- 2019-05-20 CA CA3062265A patent/CA3062265C/en active Active
- 2019-05-21 TW TW108117459A patent/TWI714092B/zh active
-
2023
- 2023-06-20 JP JP2023100937A patent/JP2023134472A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6949206B2 (ja) | 抗体薬物複合体中間体の製造方法 | |
US20230348524A1 (en) | Technologies for oligonucleotide preparation | |
EP3250238B1 (en) | Antibody drug conjugates | |
CN111620927B (zh) | 一种抗体药物偶联物中间体的一锅法制备工艺 | |
Ouyang et al. | Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation | |
EP0781778A1 (en) | Novel paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy | |
JP7167163B2 (ja) | 抗体-薬物コンジュゲートの中間体のワンポット合成法による製造プロセス | |
JP3113880B2 (ja) | パートリシン誘導体 | |
CN111670053B (zh) | 一种抗体药物偶联物中间体的一锅法制备工艺 | |
Wei et al. | Design, synthesis and biological evaluation of enzymatically cleavable NSAIDs prodrugs derived from self-immolative dendritic scaffolds for the treatment of inflammatory diseases | |
JP2001502308A (ja) | 修飾された細胞増殖抑制剤 | |
TW200927147A (en) | Improvements in or relating to compositions for the treatment or prophylaxis of viral infections | |
JP7289799B2 (ja) | オリゴペプチドリンカー中間体及びその製造方法 | |
JP2022519002A (ja) | 酸法による抗体薬物複合体中間体の調製方法及びその応用 | |
JP2024512441A (ja) | 抗体薬物複合体中間体の調製方法及び精製方法 | |
CA3076714C (en) | Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof | |
CN114796240A (zh) | 一种自组装手性短肽药物及其制备方法和应用 | |
CN115873066A (zh) | 一种抗体偶联药物连接子的合成方法 | |
Saud | Conjugation of Steroidal and Non –Steroidal Anti-Inflammatory Drugs as Possible Mutual Prodrug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210907 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210921 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6949206 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |